GlassScriptPhysician profile
Lorrie B Hayes
NPI 1225066913
$5,700.10
in general payments reported to CMS, 2019-2025
44 companies · $977 in 2025
The $977 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $120 · 2021: $370 · 2022: $971 · 2023: $1,438 · 2024: $1,309 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,723.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $996.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $695.67 | 2023-2025 | |
| Novo Nordisk INC | $557.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.25 | 2019-2024 | Jardiance |
| Exact Sciences Corporation | $371.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $339.43 | 2019-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $268.99 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Abbvie INC. | $247.78 | 2019-2025 | |
| Astellas Pharma US INC | $190.66 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $128.84 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $116.53 | 2019-2024 | Dificid, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $116.06 | 2019-2025 | Farxiga, Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $105.74 | 2022 | |
| Dexcom, INC. | $102.45 | 2023-2025 | Dexcom G6 Transmitter |
| Alk-Abello, INC | $101.61 | 2025 | Neffy, Grastek, Odactra |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorrie Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.